T-Guard clinical study of Nijmegen start-up Xenikos extends to Germany

Xenikos B.V. announced the extension of its ongoing T-Guard Phase 1/2 study to Germany after approval from the Paul Ehrlich Institute on 31 July, 2015. T-Guard™ is Xenikos’ lead compound that is being developed for treatment of Graft versus Host Disease (GVHD), a frequent and potentially life-threatening complication of bone marrow and blood stem cell transplantation. The Phase 1/2 trial, which began in The Netherlands in March 2014, will be extended to the University Hospital of Muenster, in Germany.

Read the full press release.

Xenikos first evaluated the safety and efficacy of T-Guard in 2001 in a clinical pilot study at the Radboud University Medical Centre in Nijmegen, the Netherlands and is supported by SMB Life Sciences.